AMREP, through its subsidiaries, is engaged in the real estate business. The company conducts its real estate business primarily in the City of Rio Rancho and certain adjoining areas of Sandoval County, NM. The company sells both developed and undeveloped lots to national, regional and local homebuilders, commercial and industrial property developers and others. The company also acquires land, focusing primarily in New Mexico, after completion of market research, soil tests, environmental studies and other engineering work, a review of zoning and other governmental requirements, discussions with homebuilders or other end-users of the property and financial analysis of the project and estimated development costs.

Atreca is a clinical-stage biopharmaceutical company utilizing its platform to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. The company's primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. The company owns worldwide rights to ATRC-101.

BioLife Solutions develops, manufactures and markets biopreservation tools for cells and tissues. The company's product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company's clinical grade HypoThermosol? FRS and CryoStor? biopreservation media products are marketed to the regenerative medicine, biobanking, and drug discovery markets. The company's customers include cell and gene therapy companies, research institutions, hospital-based stem cell transplant centers, and pharmaceutical companies.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform that discovers and develops peptide-based drug candidates. The company's product candidates include: PTG-300, which is an injectable hepcidin mimetic for the treatment of patients with beta-thalassemia; PTF-200, which is an oral gastrointestinal (GI)-restricted Interleukin-23 receptor antagonist peptide product candidate for the treatment of inflammatory bowel disease (IBD); and PN-943, which is an oral, alpha-4-beta-7 antagonist for the treatment of IBD. The company is researching oral and injectable peptide-based product candidates for a range of conditions including hematology and GI diseases.

Quest Resource Holding is a provider of reuse, recycling, and disposal services. The company provides businesses across industry sectors with single source solutions for the reuse, recycling, and disposal of a variety of waste streams and recyclables generated by their operations. The company's customers are multi-location businesses for which it creates, implements, and manages customer-specific programs for the collection, processing, recycling, disposal, and tracking of waste streams and recyclables. The company's sustainability programs include planning, writing policies and procedures, LEED certification, life cycle assessment, energy modeling, building commissioning, and carbon emission reduction reporting.